The Meningococcal Vaccine Market is poised for substantial growth from 2024 to 2034. With an initial valuation of USD 3,950.2 million in 2024, the market is projected to achieve an impressive USD 9,014 million by 2034, reflecting a compound annual growth rate (CAGR) of 8.6%. This growth is driven by increasing vaccination initiatives, the rising incidence of meningococcal infections, and the global emphasis on preventive healthcare measures.
Demand for meningococcal vaccines is increasing due to heightened awareness of meningitis outbreaks and the availability of conjugate and multivalent vaccines. Government-backed immunization programs and mandates for vaccination in schools and universities are further driving market demand, especially in regions with significant disease burden.
Technological advancements are playing a pivotal role, with pharmaceutical companies developing improved, multivalent vaccines that cover more meningococcal serogroups. These vaccines offer broader protection, enhancing global acceptance and uptake. Major players in the market are engaged in partnerships and licensing agreements to boost production capacities and meet surging demand.
However, the high cost of meningococcal vaccines and supply chain disruptions present challenges. Despite this, the growing involvement of health organizations like the World Health Organization (WHO) and Gavi, the Vaccine Alliance, to promote meningitis prevention in low-income regions is expected to bridge these gaps, ensuring sustained market growth over the next decade.
Get Full Report Now - https://www.globenewswire.com/news-release/2024/12/19/2999459/0/en/Meningococcal-Vaccine-Market-is-Set-to-Grow-from-USD-3-950-2-Million-in-2024-to-USD-9-014-Million-by-2034-Registering-a-Robust-CAGR-of-8-6-FMI.html
Country-wise Insights
The section presents a regional study of the worldwide meningococcal vaccination market in the near future. According to these figures, Western countries such as the United States and the United Kingdom are quite likely to see strong development during the next ten years. China is also one of the most profitable countries in this sector in Asia.
Countries CAGR 2024 to 2034
The United Kingdom 9.8%
The United States 9.4%
China 9.5%
France 9.0%
Germany 8.7%
Key Takeaways from Market Study
• Market Size Growth: The global meningococcal vaccine market will grow from USD 3,950.2 million in 2024 to USD 9,014 million by 2034, with a CAGR of 8.6%.
• Increasing Adoption of Multivalent Vaccines: Vaccines like MenACWY are rapidly gaining preference due to their coverage of multiple meningococcal serogroups, ensuring higher demand from healthcare providers.
• Government-Backed Vaccination Mandates: Vaccination requirements for students and travelers are driving consistent demand across educational institutions and immigration protocols.
• Shift Toward Conjugate Vaccines: Conjugate vaccines, known for their long-term immunity, are rapidly replacing polysaccharide vaccines. This shift will remain a key market growth factor.
• Technological Innovation: R&D to develop novel vaccines for emerging meningococcal serogroups presents future opportunities for market expansion.
• Regional Variations: North America and Europe remain dominant markets, while Asia-Pacific offers untapped potential, especially with growing government immunization initiatives.
"The Meningococcal Vaccine Market is on a robust growth trajectory due to the confluence of strong government mandates, rising public health awareness, and ongoing R&D efforts. The market's growth is further supported by international vaccination programs in lower-income regions and the introduction of multivalent vaccines, which provide wider protection. With an 8.6% CAGR expected over the next decade, stakeholders should focus on capacity expansion, technological advancement, and partnerships with health organizations to drive sustainable growth." Says Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)
Key Market Insights
Rising Incidence of Meningococcal Disease: In 2019, there were approximately 2.51 million cases of meningitis globally, with a notable number of cases occurring in children under five years old. This alarming prevalence has heightened public concern and increased vaccination efforts.
Growing Awareness: There is an increasing awareness among healthcare professionals and the general public about the seriousness of meningococcal disease, which is contributing to higher vaccination rates.
Government Initiatives: Many countries have implemented national immunization programs targeting infants, adolescents, and young adults to curb the incidence of meningococcal disease. These initiatives are crucial in driving market growth.
Advancements in Vaccine Development: Ongoing advancements in vaccine technology are leading to the development of more effective meningococcal vaccines that provide broader protection against multiple strains and require fewer doses.
Healthcare Infrastructure: Countries with well-established healthcare systems, such as the United States and the United Kingdom, are seeing a trend towards increased vaccination against meningococcal disease.
Conjugate vaccines play a crucial role in the meningococcal vaccine market by providing effective and long-lasting protection against meningococcal disease, which is caused by the bacterium Neisseria meningitides. Here are the key contributions of conjugate vaccines to the market:
Key Contributions of Conjugate Vaccines
Enhanced Immunogenicity: Conjugate vaccines link polysaccharide antigens from the bacteria to a protein carrier, which significantly enhances their immunogenicity. This results in a stronger and more robust immune response compared to traditional polysaccharide vaccines, particularly in young children who are at higher risk for meningococcal disease
Long-lasting Protection: These vaccines induce immunologic memory, meaning that they can provide longer-lasting protection against meningococcal infections. This is particularly important for populations that require sustained immunity, such as infants and young children
Effectiveness Against Multiple Serogroups: Many conjugate vaccines are designed to protect against multiple serogroups of Neisseria meningitides, including A, C, W, and Y. This multivalent approach simplifies vaccination schedules and increases overall vaccine coverage, which is critical for controlling outbreaks
Reduction of Nasopharyngeal Carriage: Conjugate vaccines have been shown to reduce nasopharyngeal carriage of the bacteria, thereby interrupting transmission within communities. This contributes to herd immunity and protects individuals who may not be vaccinated
Government and Public Health Initiatives: The introduction of conjugate vaccines has been supported by various government initiatives and public health programs aimed at increasing vaccination rates and reducing the incidence of meningococcal disease. Many countries have incorporated these vaccines into their national immunization schedules, recognizing their importance in preventing outbreaks
Regional Analysis of Meningococcal Vaccine Market
• North America: Largest share due to strong immunization mandates, high healthcare spending, and established vaccine providers.
• Europe: Significant share due to national immunization programs and strong government regulations on student vaccinations.
• Asia-Pacific: Fastest-growing region, driven by increasing government initiatives, rapid urbanization, and growing healthcare infrastructure.
• Latin America: Increasing awareness and partnerships with health organizations to expand vaccination coverage.
• Middle East & Africa: High disease burden has prompted Gavi and WHO-led campaigns, boosting vaccine distribution in underserved regions.
Competition Outlook
The competitive landscape of the global meningococcal vaccine market is primarily driven by innovations in vaccine formulations. The consumer base of the company in the industry totally depends on the efficiency, cost, and safety profile of the vaccine they formulate. Companies are also tying up with government and international organizations to expand their market reach and ensure wider vaccine accessibility.
Some of the most prominent companies in the industry are GlaxoSmithKline plc, Pfizer Inc., Sanofi Pasteur, Merck & Co., Inc., and Novartis AG.
Industry Updates
• In April 2024, Nigeria made history by introducing the world's first 5-in-1 meningitis vaccine, Men5CV. The vaccine, recommended by WHO, aims to combat the deadly disease, with an initial campaign targeting over one million people aged 1-29.
• In November 2023, GlobalData reported significant changes in the meningococcal vaccine market with the launch of Pfizer's Penbraya. The CDC's Advisory Committee on Immunisation Practices recommended administering Penbraya alongside MenACWY and MenB vaccines for eligible patients aged 10 years and older.
• In July 2023, the Serum Institute of India announced that its multivalent meningococcal meningitis vaccine, designed to combat the five predominant strains in Africa, had received WHO prequalification. This approval made the vaccine eligible for procurement by UN agencies and Gavi, the Vaccine Alliance.
Leading Meningococcal Vaccines Brands
1. GlaxoSmithKline plc
2. Pfizer Inc.
3. Sanofi Pasteur
4. Merck & Co., Inc.
5. Novartis AG
6. CSL Limited
7. Johnson & Johnson
8. Bharat Biotech International Limited
9. Serum Institute of India Pvt. Ltd.
10. Sinovac Biotech Ltd.
11. Biological E Limited
12. Chongqing Zhifei Biological Products Co., Ltd.
13. Beijing Tiantan Biological Products Co., Ltd.
14. Hualan Biological Engineering Inc.
15. Walvax Biotechnology Co., Ltd.
16. Bio-Manguinhos (Fiocruz)
17. Hangzhou Jinjiang Group Co., Ltd.
18. Shenzhen Kangtai Biological Products Co., Ltd.
19. Biomed Pvt. Ltd.
20. GlaxoSmithKline Biologicals SA
